Flumetholon 0.1%

Quick links

Choose a section

Quick links to important sections

Advertisements

Flumetholon 0.1%

Advertisements
Advertisements

Method of action: Ophthalmologicals

Treatment option:

Advertisements

Overview of Flumetholon 0.1%

Quick Facts

Property Description
Active Ingredient Fluorometholone (INN)
Form Sterile Ophthalmic Suspension (Eye Drops)
Pharmacological Class Corticosteroid / Glucocorticoid
General Purpose Anti-inflammatory effect
Origin Synthetic Fluorinated Compound

Composition and Classification

Flumetholon 0.1% is a prescription-only pharmaceutical preparation delivered as a sterile ophthalmic suspension intended for topical ophthalmic administration. The preparation's core identity is the active ingredient, Fluorometholone, which is a synthetic fluorinated corticosteroid present at a 0.1% concentration.

This classification signifies that the substance is not naturally occurring but is instead a chemically synthesized derivative designed to act as a potent glucocorticoid. This specific formulation is clinically recognized for balancing high efficacy against inflammatory processes while having a comparatively lower propensity to cause a rise in intraocular pressure than some other ocular steroids. This favorable profile is a key aspect of this medicine's design for managing eye inflammation.

What is the General Purpose of Fluorometholone?

The fundamental purpose of the Fluorometholone component is to exert a powerful, localized anti-inflammatory effect within the eye's anterior segment. As a corticosteroid, its mechanism involves modulating the inflammatory cascade by binding to specific intracellular receptors.

This action allows the medicine to comprehensively suppress the localized signs of inflammation, which include reducing swelling, alleviating redness, and inhibiting the production of various inflammatory chemical signals. For instance, it is commonly used in contexts where a corticosteroid-responsive inflammation is anticipated, such as following routine eye procedures. This confirms that the primary function of the medicine is to calm the immune response in the eye.

Understanding the Ophthalmic Suspension Form

The specific dosage form of Flumetholon 0.1% is an ophthalmic suspension, meaning the Fluorometholone is dispersed as fine, solid particles within an aqueous vehicle. This suspension format is deliberately chosen over a true solution because it facilitates a prolonged interaction between the active substance and the surface of the eye. The sustained presence of the synthetic fluorinated corticosteroid is crucial for maximizing its local absorption and ensuring the comprehensive suppression of inflammatory signals exactly where they are required.

Advertisements

What side effects are possible with Flumetholon 0.1%?

Adverse Effects and Safety Profile

Serious and Clinically Significant Adverse Reactions

The most significant risks associated with prolonged use of ophthalmic corticosteroids are ocular and include increased intraocular pressure (IOP), which may lead to glaucoma, damage to the optic nerve, and defects in visual acuity and fields of vision. Prolonged treatment is also associated with posterior subcapsular cataract formation. Due to suppression of the host response, there is an increased hazard of secondary ocular infections (bacterial, fungal, or viral). In diseases that cause thinning of the cornea or sclera, perforation of the globe has been reported.

Rare systemic effects, such as Cushing's syndrome and adrenal suppression, have been reported after very frequent use of topical ophthalmic corticosteroids, particularly in very young children.

Common and Occasional Adverse Reactions

Adverse effects reported with a higher frequency (common) often include ocular irritation, such as mild stinging or burning upon instillation, and a foreign body sensation in the eye. Other reported ocular reactions include blurred vision, eye discharge, eye pain, eye pruritus, eyelid edema, eyelid erythema, and increased lacrimation.

Contraindications and Restrictions

This medication is strictly contraindicated in the presence of most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis, vaccinia, and varicella, as well as in ocular mycobacterial and fungal infections. The steroid can mask or exacerbate acute purulent (untreated) infections.

If the product is used for 10 days or longer, intraocular pressure must be routinely monitored to detect corticosteroid-induced IOP elevation. Caution is advised in patients with pre-existing glaucoma. Patients using soft contact lenses must remove them prior to application and wait 15 minutes before reinserting, as the preservative (benzalkonium chloride) may be absorbed by the lenses.

Advertisements

Overdose and Emergency Response

Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Presentations Ocular overdose is not likely to be associated with toxicity following excessive topical application. Accidental ingestion is also unlikely to be associated with toxicity [FDA Labeling].
Physiological Systems Affected The Hypothalamic-Pituitary-Adrenal (HPA) axis is the key systemic concern, with documented potential for adrenal suppression following misuse [FDA Labeling].
Dose-Related or Exposure-Related Factors Risk of severe outcomes is linked to very frequent use over prolonged periods, rather than a single acute over-application.
Population-Specific Overdose Notes Very young children are explicitly noted to be at an increased risk of developing Cushing's syndrome and HPA axis suppression following very frequent use [FDA Labeling].

Immediate Actions and When to Seek Urgent Help

Action Aspect Official Regulatory Statement
Emergency Response Statements Seek immediate medical attention. Management is symptomatic and supportive treatment. No specific antidote is known or documented.
When Immediate Medical Help is Required Contact a Poison Control Center or Emergency Room at once if overdosage is suspected [NIH / DailyMed Guidance].

Connection to the Overall Overdose Profile

The regulatory profile establishes that an acute ocular overdosage is unlikely to be associated with toxicity, owing to the limited systemic absorption of the ophthalmic formulation. However, regulatory guidance mandates immediate contact with emergency services for suspected overdosage, with treatment focusing on symptomatic and supportive measures given the absence of a known antidote. The severe complications listed are the rare, chronic systemic effects of corticosteroids, such as adrenal suppression, which are associated with high frequency of use, particularly in susceptible populations.

Advertisements

Therapeutic Uses of Flumetholon 0.1%

Understanding Flumetholon 0.1%

Flumetholon 0.1% is an ophthalmic solution containing fluorometholone, a corticosteroid formulated for topical application to the eyes. It is primarily utilized to manage various inflammatory conditions affecting the anterior segment of the eye.

Main Uses

This medication is indicated for the treatment of non-infectious inflammatory diseases of the eye. Its primary applications include:

  • External and Anterior Eye Inflammation: It is used to reduce swelling, redness, and irritation associated with conditions such as blepharitis (eyelid inflammation), conjunctivitis (inflammation of the membrane covering the white of the eye), and keratitis (inflammation of the cornea).
  • Scleritis and Episcleritis: The solution helps manage inflammation in the deeper and superficial layers of the white of the eye.
  • Iritis and Iridocyclitis: It addresses inflammation of the iris and the surrounding ciliary body.
  • Post-Operative Management: It is often employed to control inflammatory responses following ophthalmic surgical procedures.

Benefits and Mechanism of Action

The active ingredient, fluorometholone, works by inhibiting the inflammatory response to various inciting agents. By modulating the body's immune response within the ocular tissues, it provides several therapeutic benefits:

Reduction of Physical Discomfort

By suppressing the production of inflammatory mediators, the medication helps alleviate common symptoms of ocular distress, including itching, burning sensations, and the feeling of a foreign object in the eye.

Resolution of Redness and Edema

The corticosteroid aids in constricting dilated blood vessels and reducing fluid accumulation in the eye tissues, which helps restore the eye's normal appearance and reduces swelling.

Prevention of Tissue Damage

Persistent inflammation can lead to scarring or permanent damage to delicate structures like the cornea. By managing the inflammatory process effectively, the medication helps maintain the integrity of the ocular surface and clear vision.

Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for Fluorometholone ophthalmic suspension (Flumetholon 0.1%) establishes specific population eligibility rules, primarily based on infection risk and patient history.

Contraindicated Populations

Use of the medicine is absolutely contraindicated in patients with specific active ocular infections. This prohibition includes acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral, mycobacterial, or fungal diseases of the eye. The medicine must also not be used by individuals with a known or suspected hypersensitivity to the active ingredient or other components.

Age-Group Eligibility

Use is established for adults and older adults. However, safety and effectiveness are not established in the general pediatric population. For children aged two years and younger, use requires caution and should be limited.

Conditional Use and Restrictions

Use requires great caution and frequent monitoring in patients with a history of ocular herpes simplex infection or those with glaucoma. Patients with pre-existing conditions causing thinning of the cornea or sclera must also be used cautiously due to the risk of perforation. For pregnant women and those who are nursing, use is generally not recommended and is only permitted if the potential benefit justifies the potential risk to the fetus or infant. Eligibility is not established for patients with hepatic or renal impairment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flumetholon 0.1% (Fluorometholone ophthalmic suspension) has a limited profile of formally documented drug interactions, primarily due to its topical ophthalmic route of administration.

Documented Interaction Patterns

Interaction Type Interacting Substances/Category Official Restriction or Outcome
Pharmacodynamic Interaction Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration may increase the potential for corneal healing problems [Source 2.3].
Pharmacokinetic Interaction CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat) Co-treatment may increase systemic exposure to Fluorometholone, raising the risk of systemic corticosteroid side effects [Source 2.3, 2.4].
Administration Timing Rule Other Ocular Medications (Drops/Ointments) Flumetholon 0.1% must be administered 5 to 10 minutes after any preceding eye medication [Source 3.2, 3.3].

No medicinal product is formally listed as contraindicated for co-administration due to a drug–drug interaction risk in the official prescribing information. No specific interactions with food, alcohol, or herbal products are documented in the regulatory labeling for the ophthalmic suspension. The regulatory documents define the product’s interaction structure primarily through a local additive effect with topical NSAIDs and a cautious note regarding systemic exposure when co-administered with specific enzyme inhibitors.

Advertisements

Mechanism of Action

Flumetholon (fluorometholone) is a synthetic glucocorticoid that exerts its effects through binding to specific cytosolic glucocorticoid receptors (GRs) found within target cells. The drug acts as an agonist for these receptors.

Upon binding, the newly formed steroid-receptor complex undergoes nuclear translocation, moving into the cell nucleus. Inside the nucleus, this complex interacts with specific DNA sequences known as Glucocorticoid Response Elements (GREs), as well as modulating the activity of various transcription factors like NF-kB and AP-1.

This genomic and non-genomic modulation affects gene transcription. The primary intracellular consequence is the upregulation of anti-inflammatory proteins such as lipocortin-1 (annexin A1) and the downregulation of pro-inflammatory gene expression.

Specifically, lipocortin-1 inhibits the enzyme phospholipase A2 (PLA2), thereby blocking the release of arachidonic acid—a crucial precursor for eicosanoids, including pro-inflammatory prostaglandins and leukotrienes. The resulting cascade effectively suppresses the cellular production of key inflammatory mediators, including various cytokines, chemokines, and adhesion molecules. This overall action modifies the physiological characteristics of inflammation, including inhibition of edema, fibrin deposition, capillary dilation, and the migration and accumulation of leukocytes at the affected site.

Advertisements

Dosage and Administration Information

Administration and Preparation

Flumetholon 0.1% is a sterile ophthalmic suspension intended for topical administration solely into the conjunctival sac; it is strictly not for injection. Prior to use, the bottle must be shaken well to ensure the uniform dispersion of the 0.1% active ingredient.

Dosing Schedule and Frequency

The standard administration involves the instillation of one drop into the affected eye(s), typically at a frequency of two to four times daily. For the management of acute inflammation, the frequency may be temporarily increased to as often as every two hours during the initial 24 to 48 hours of treatment.

Course Duration and Discontinuation

Treatment duration is structured around frequent monitoring. If signs of inflammation or symptoms fail to improve after two days of initial therapy, the regimen requires re-evaluation. The protocol for discontinuation, especially in long-term scenarios, requires that the treatment is not stopped abruptly. Instead, usage must be concluded by gradually decreasing the frequency of applications over a controlled period.

Procedural Constraints

To manage systemic exposure, pressure is to be applied to the tear duct (nasolacrimal occlusion) immediately following the application of the drops. If soft contact lenses are worn, they must be removed prior to instillation and should not be reinserted for at least 15 minutes afterward. Furthermore, the safety and effectiveness have not been established for use in pediatric patients under 2 years of age.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flumetholon 0.1%


Evidence for Steroid-Responsive Anterior Eye Inflammation

This section will summarize the foundational clinical trials and regulatory evidence that characterize the clinical evaluation of the medicine for anterior eye inflammation. It will describe the types of studies that measured changes in objective signs like inflammation scores and how patient symptoms were documented.

The foundational research for Fluorometholone 0.1% was studied in the context of various anterior segment inflammatory conditions, such as different forms of keratitis and uveitis. These studies primarily focused on adult patient populations and those recovering from certain eye surgeries. Researchers monitored objective physical signs of inflammation, including measuring the degree of swelling, redness, and the presence of inflammatory cells inside the eye.

Findings describe patterns observed in these studies where physical signs of inflammation were measured during the short-term treatment course. However, research so far indicates that follow-up durations were limited, typically focusing only on the acute phase. Long-term outcomes for patients requiring repeated or extended courses of treatment are not fully established.


Evidence for Use in Dry Eye Disease (DED) Exacerbations

This block will detail the structure of the controlled clinical trials, including randomized vehicle-controlled studies, that have examined the short-term evaluation of this suspension in adults with inflammation associated with certain forms of DED. It will focus on the research endpoints, such as measuring changes in ocular surface staining and symptom scores.

Research has examined the application of this suspension for individuals with conditions characterized by fluctuating or episodic manifestations of DED. This was examined in randomized, double-masked, vehicle-controlled trials where adults with moderate to severe DED was studied. Outcomes monitored included physical signs of damage to the eye’s surface, measured by corneal and conjunctival staining scores.

Findings indicate that the observed populations had documented outcomes that were numerically different in the change of staining scores across the studied groups. The evidence for use in DED is limited to short-term treatment courses (e.g., around three weeks), meaning that the research provides limited insight into long-term management of this chronic condition.


Research on Post-Operative and Specific Surgical Outcomes

The suspension was evaluated in specific research contexts, and research examined post-operative outcomes following certain eye surgeries. This includes preliminary dose-ranging trials where the medicine was observed in adult populations undergoing complex lid procedures for Trachomatous Trichiasis (TT).

In these specific trials, researchers focused on long-term outcomes of the surgery itself, tracking patients for up to one year. Research describes the patterns observed in the rates of recurrence across the studied groups. The research available in this area is limited because these are often preliminary studies used for dose finding, and comparative evidence is lacking for generalization to other common eye surgeries.


Evidence in Special Populations

Data for certain groups remain limited. The majority of the clinical research was evaluated in the adult population. The regulatory research record does not determine the full safety and effectiveness profile for pediatric patients under 2 years of age. For children 2 years of age and older, data for this subgroup are limited, and research provides limited insight into how outcomes may differ compared to adults.

Key Studies & References

  1. FLUOROMETHOLONE OPHTHALMIC SUSPENSION- fluorometholone suspension/ drops - DailyMed
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Flumetholon 0.1% (FAQ)


Q: Is Flumetholon 0.1% considered a strong or weak steroid for the eye?

Flumetholon 0.1% contains Fluorometholone, which is a potent synthetic glucocorticoid derivative. Regulatory summaries indicate that while effective for inflammation, it is associated with a lower tendency to raise pressure inside the eye compared to some other steroids. This comparative IOP profile is a factor in its classification relative to other ocular steroids.


Q: Why is Flumetholon typically used only for short-term eye inflammation?

According to official product information, treatment duration is usually limited because prolonged or extended use of any ophthalmic steroid is associated with a risk of serious adverse effects. These risks include the potential for increased intraocular pressure (glaucoma) and the formation of cataracts.


Q: Does Flumetholon 0.1% slow down wound healing in the eye?

Official labeling advises that corticosteroids generally delay or slow healing. Specifically, the use of topical ophthalmic corticosteroids may be associated with slowed corneal wound healing.


Q: How soon can a person expect the inflammation to start going down?

The time to initial symptom improvement can vary among individuals. While the anti-inflammatory effect may begin within a few hours, regulatory labels require that if signs of inflammation fail to improve after two days of initial therapy, the treatment plan must be re-evaluated by a healthcare professional.


Q: What is the difference between Flumetholon 0.1% and other steroid eye drops like prednisolone?

Official documents characterize a distinction based on the fact that Fluorometholone has a lower potential to raise intraocular pressure (IOP) compared to prednisolone. This lower IOP-raising tendency is a key characteristic of the drug, although prednisolone is generally considered the more potent anti-inflammatory agent.


Q: How quickly can a person's IOP increase after starting Flumetholon?

Clinical monitoring has shown that in a small percentage of documented steroid-responders, a significant rise in intraocular pressure (IOP) has been reported to occur within one week of starting steroid drops. For treatment lasting longer than 10 days, official labels state that frequent monitoring is required due to this risk.


Q: What are the signs of an allergic reaction to Flumetholon?

Regulatory sources advise that symptoms of an allergic (hypersensitivity) reaction may include a rash, hives, swelling of the face, lips, tongue or throat, or difficulty breathing. Due to the seriousness of these symptoms, they must be brought to the attention of a healthcare professional immediately.


Q: Why is it prescription-only?

The medication is prescription-only because its use requires specialized medical supervision. The label states that the prescription and renewal require examination by a doctor after examination with the aid of magnification (such as a slit lamp) to monitor for serious adverse effects like glaucoma and cataracts.


Q: Does Flumetholon 0.1% cause changes in taste?

Taste perversion (or a taste disorder) has been reported as an adverse reaction associated with the use of ophthalmic fluorometholone in regulatory documents.


Q: What is the usual total duration of treatment with Flumetholon drops?

The usual total duration of treatment is determined by the prescribing doctor based on the patient's condition. However, official labeling generally advises that the medicine should not be used beyond 10 days unless strictly necessary, and only under regular ophthalmologic monitoring due to safety risks.


Q: How does the body process or eliminate Flumetholon from the eye? (Pharmacokinetics)

Official pharmacokinetic properties indicate that following local administration, the drug is metabolized to some extent while penetrating the eye. This is evidenced by a rapidly forming metabolite that occurs at high concentrations in the aqueous humor and cornea.


Q: Is it safe to drive or operate machinery immediately after using Flumetholon 0.1%?

Official regulatory labeling advises caution. Vision may be temporarily blurred after using the drops. The warning indicates that operating machinery or driving should be avoided until vision is clear.


Q: Is there a generic version of Flumetholon 0.1% available?

The active ingredient, Fluorometholone 0.1% ophthalmic suspension, is available under its generic name (USP) and various brand names.


Q: Can the drops be used past the expiration date on the bottle?

Official guidance requires that the product be discarded after the printed expiration date. The product must also be discarded one month (28 days) after first opening to maintain sterility.


Q: What should be done if the medicine is accidentally swallowed?

If the medicine is accidentally swallowed (ingested), official guidance regarding accidental ingestion suggests drinking fluids to dilute the product. Acute systemic problems from the small topical dose are not typically expected.


Q: What is the purpose of the phosphates mentioned in the ingredient list?

Phosphates (such as sodium phosphate dibasic) are listed as inactive ingredients, or excipients. These substances are typically used as buffers in the formulation to ensure the eye drop has the correct pH and osmolality (salt balance) for optimal use in the eye.

Advertisements

How should Flumetholon 0.1% be stored and disposed of?

How to Store and Dispose of Flumetholon 0.1%

Flumetholon 0.1% (fluorometholone ophthalmic suspension) must be stored and handled according to official regulatory guidelines to maintain its stability and sterility.


Storage Conditions

  • Temperature: Store at controlled room temperature, typically between 15 C to 25 C (59 F to 77 F). The product must be protected from freezing.
  • Container Handling: The bottle must be shaken well before each use and kept tightly closed when not in use. To prevent contamination, the dropper tip must not touch any surface.
  • Child Safety: Always keep the medicine out of the sight and reach of children.

Stability and Disposal

  • In-Use Period: The product must generally be discarded 28 days after first opening to prevent microbial contamination.
  • Disposal: Do not dispose of this medicine in household waste or pour it into wastewater. Consult a pharmacist or local waste authority for instructions on how to properly discard any unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flumetholon 0.1% found in:

A-Z Index: